Tarlatamab for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your prostate cancer must have spread to other parts of the body (metastatic).
- Your cancer must have gotten worse after at least one prior treatment for metastatic disease.
- A recent biopsy must show that your cancer cells have a protein called DLL3 on at least half of them.
- You must have good organ function (kidney, liver, blood counts) and be able to breathe normally on room air.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.